title: Design of innovative therapeutics for pharmacoresistant epilepsy: challenges and needs.
abstract: Effective therapy for pharmacoresistant epilepsy is an unmet clinical need. Pharmacologically, there are two logical approaches: super-antiictogenic drugs (SAIDs) or antiepileptogenic agents. However, can either of these agents be successfully designed and developed? Designing SAIDs or antiepileptogenics will require applying the techniques of twenty-first century drug design to this ancient "sacred disease." Before this task can be effectively realized, five fundamental needs will first have to be addressed: need for antiepileptogenic drug targets, need for druggable targets for SAIDs, need for new drug molecule platforms, need for new and relevant animal models, and need for innovative funding strategies.
authors: Department of Medicine Neurology and Chemistry, Dalhousie University, Halifax, Nova Scotia, Canada. donald.weaver@dal.ca
authors: Donald F
authors: DF
authors: Weaver
mesh_terms: D000818:Animals; D000927:Anticonvulsants / Q000737:chemistry / Q000627:therapeutic use*; D015195:Drug Design; D055808:Drug Discovery / Q000639:trends*; D004351:Drug Resistance / Q000187:drug effects; D004827:Epilepsy / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D006301:Health Services Needs and Demand / Q000639:trends*; D006801:Humans
chemical_list: D000927:Anticonvulsants